ZyVersa TherapeuticsZVSA
Market Cap: $2.58M
About: ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Employees: 7
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.28% less ownership
Funds ownership: 1.5% [Q1] → 1.23% (-0.28%) [Q2]
50% less funds holding
Funds holding: 8 [Q1] → 4 (-4) [Q2]
54% less capital invested
Capital invested by funds: $84.9K [Q1] → $38.7K (-$46.1K) [Q2]
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for ZVSA.